ERBB2 and breast carcinoma: This led to the creation of a Her-DTX-NPs formulation that enables the sustained, controlled, and precise transportation of docetaxel specifically to breast cancer cells.176 This drug delivery system displayed improved stealth properties and cellular uptake efficiency, and was also proved to be more cytotoxic to HER2-overexpressing cancer cells.